eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
4/2024
vol. 11
 
Share:
Share:
abstract:
Case report

Personalized biological treatment with lanadelumab in a patient with recurrent attacks of hereditary angioedema

Artur Gęsicki
1
,
Maciej F. Kozlowski
1
,
Karolina Żurawska
1
,
Weronika Ossowska
1
,
Jakub Sikora
1
,
Szymon Dyguś
1
,
Iwona Poziomkowska-Gęsicka
1

  1. Department of Clinical Allergology, Pomeranian Medical University, Szczecin, Poland
Alergologia Polska – Polish Journal of Allergology 2024; 11, 4: 332–334
Online publish date: 2024/08/29
View full text Get citation
 
PlumX metrics:
Hereditary angioedema (HAE) is an autosomal dominantly inherited disease caused by deficiency of C1 esterase inhibitor protein type 1 (about 85% of patients with HAE-C1-INH) or type 2 oedema (about 15% of patients with HAE-C1-INH) by C1 inhibitor dysfunction, with normal serum levels (HAE-2). Long-term treatment to prevent further attacks consists of continuous and regular administration of medications to reduce the number and severity of oedema attacks in HAE patients, thereby reducing the indirect burden of the disease. With the severe course of the disease, potentially life-threatening during flare-ups, it is expedient to implement long-term HAE attacks prophylaxis, which was very limited in Poland until September 2021.
keywords:

congenital angioedema, hereditary angioedema, lanadelumab, hereditary angioedema, biological treatment



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.